Curaleaf Aurora Takeover Bid Raised to US$5|Higher Price, Still 80% Curaleaf Stock?

Chapter 1: What the 5 dollars really is

Curaleaf has raised its hostile takeover offer for Aurora Cannabis to 5 U.S. dollars a share. Curaleaf says that answers the question of value, yet Aurora's board has told shareholders to do nothing. The new terms are one U.S. dollar in cash plus 0.4013 of a Curaleaf share, for each Aurora share. Curaleaf has filed the change with Canadian regulators and moved its deadline to December 4.

Curaleaf's chief executive, Boris Jordan, said on X that if value was Aurora's concern, the enhanced offer addresses it. Aurora's board says its review has only begun, and that holders should not tender until it reports. Here is the reading the record supports so far. This raise is an answer to Aurora's complaint about price. It is not yet an answer to the board's other objections.

Curaleaf calls the new terms a 25 per cent increase. Its first offer, launched in August, was valued at 4 U.S. dollars a share. Both of those numbers are snapshots. Each one prices the Curaleaf shares at a single day's close: an August close for the first offer, the October 2 close for the new one. And most of the package is stock. At the October 2 price, Curaleaf shares make up about 4 of the 5 dollars.

That is 80 per cent of the offer. The cash slice barely moved, from about 19 per cent of the first offer to about 20 per cent now. That changes how to read the headline. Curaleaf's stock was worth more on October 2 than on August 10. So part of the jump came from Curaleaf's own share price, not from the new terms. Value the original terms at the same October 2 price, and they come to about 4 dollars and 20 cents.

The new terms come to 5 dollars. So the improvement Curaleaf added, measured on the same day, is about 80 cents a share. That is roughly 19 per cent. That is still a real raise. But the 5 dollars is not a fixed price. It is what 0.4013 of a Curaleaf share was worth at one Friday's close, plus a dollar in cash. For Aurora's owners, the price question has become a question about Curaleaf's stock.

Chapter 2: A higher ceiling, the same downside

Because the stock portion floats, Curaleaf built in a ceiling. The new terms lift it from 5 to 6 U.S. dollars per Aurora share. It works through Curaleaf's share price. If Curaleaf's 20-day volume-weighted average rises above 17.76 Canadian dollars, the exchange ratio steps down. That trigger sits about 25 per cent above the 14.21 dollar close used to price the offer.

Past that point, Aurora's owners stop sharing in Curaleaf's gains. The cash is fixed. The stock portion leaves Aurora's owners exposed to changes in Curaleaf's share price, subject to that cap. Those changes are not small. Curaleaf shares fell about 3 per cent on October 1. They fell another 3 per cent on October 2, the very close used to set the 5 dollar value.

In September, Aurora's chief executive, Miguel Martin, said the bid offered "intentionally limited upside." Curaleaf's fact sheet called concerns over the earlier cap a distraction from the premium. The raise lifted that ceiling by a dollar. It did not change who carries the downside. So the reading narrows: the raise did touch one structural complaint, the cap, but only from above.

Chapter 3: What Aurora's owners would hold

The board's deeper objection is about the two balance sheets. Aurora reported nearly 149 million U.S. dollars in cash as of June 30, and no debt. Curaleaf carries more than 1 billion dollars of debt. Its filings include 10 per cent senior secured notes due in December 2027. Aurora argues the deal would give Curaleaf control of that cash, while moving Curaleaf's balance-sheet risk onto Aurora's owners.

Curaleaf replies that its debt is backed by strong cash flows. Curaleaf's own figures show how much that cash matters. It says the new offer is an 86 per cent premium to Aurora's unaffected price of 2.75 dollars. Then it strips out Aurora's cash, including money from new shares sold in its fiscal first quarter. On that basis, Curaleaf puts the premium at 217 per cent. The gap between those two premiums is the point.

By Curaleaf's own framing, much of what Aurora was worth before the bid was cash. That cash has become a battleground. Curaleaf asked securities regulators to stop Aurora from selling shares through its at-the-market program. Curaleaf argued new issuance could interfere with the bid; Aurora called it another attempt to pressure shareholders. On the new terms, the two chief executives talk past each other.

Curaleaf's Boris Jordan wrote: "Actions speak louder than words." Aurora's Miguel Martin said the filing is "simply the next step in the process, not a deadline to make a decision." Neither line addresses what the new terms leave unchanged. Aurora's owners would still be paid in Curaleaf subordinate voting shares. Under the original terms, Aurora's owners would have held about 7.7 per cent of the combined company.

Because of Curaleaf's multiple-voting shares, they would have held only 3.2 per cent of the votes. The higher exchange ratio gives Aurora's owners somewhat more Curaleaf stock. The share class stays the same, so the gap between ownership and votes stays built in. Curaleaf's answer is scale. It says the combined company, valued above 3 billion dollars, would have a lower cost of capital than Aurora has today.

So the dispute has shifted. It is less about the headline number than about what Aurora's owners would hold. That is a smaller vote, in a company with debt, in exchange for a company with cash.

Chapter 4: Who Curaleaf is really talking to

Curaleaf is not waiting for Aurora's board. Jordan says Curaleaf has met a significant share of Aurora's investors. He said all of them are "supportive of the strategic rationale for the deal." Note the wording. Support for the rationale is not the same as a promise to tender at this price. The premium could still tempt them. According to Baystreet, Aurora's stock had fallen 94 per cent over five years.

Curaleaf's pitch leans on that history of dilution and share price decline. Jordan also added a line aimed at the process itself: "if Aurora is providing diligence access to other parties, shareholders deserve a fair and open process that includes Curaleaf." Curaleaf says its offer was built only from public information, because Aurora refused due diligence access.

In September, Aurora's board said it was exploring alternatives, according to a TipRanks summary. Jordan's line is conditional, and Aurora has not named any other buyer. What it shows is what Curaleaf is asking for: a seat in any sale process, not just a yes or no on its own bid. The market gave a cooler reading. Aurora closed at 3.92 U.S. dollars on October 2, before the new terms were announced.

On the Monday the raise was announced, it jumped 13.78 per cent, to 4.46 dollars. Curaleaf's own shares were roughly flat that morning. That close sits about 54 cents below the stated 5 dollar value. That is roughly 11 per cent. The reports do not say why. Doubt about the stock portion, or about the bid succeeding at all, could each explain it.

Either way, even on price alone, the market was not treating 5 dollars as settled.

Chapter 5: The road to December 4

Part of the earlier fight was procedural. Aurora applied to the Alberta Securities Commission over Curaleaf's original circular. It challenged the absence of pro forma financial statements and what it viewed as an inadequate deposit period. The new filing adds pro forma statements and moves the deadline from December 1 to December 4. Curaleaf says it did so voluntarily, and not because any regulator required it.

Whatever Aurora makes of those changes, Curaleaf has now answered both complaints in its own filing. That pushes the board's next answer toward substance. Aurora says the board's formal recommendation will come in a news release and a directors' circular. It says that will happen within 15 days, in line with securities law. Its October 6 filing gave no date. Aurora's owners have until at least December 4 to decide.

One more date falls inside that window. Curaleaf reports third-quarter results on November 3. That report lands while 80 per cent of the offer is still riding on Curaleaf's share price. Back to the opening clash. Curaleaf says the raise settles the question of value. Aurora's board says wait. Our reading: 5 dollars is unlikely to be enough on its own.

The raise answered price, and even that only at one day's share price. It left the debt, the votes and the cash where they were. In September, the board rejected the first bid unanimously, citing those concerns among others. So the weight leans toward a second rejection, with the contest then going straight to shareholders before December 4. Watch the directors' circular.

If it rejects the bid mainly on price, this reading is wrong: the gap is a number Curaleaf has shown it will move. If it rests on debt, votes and cash, Aurora's board keeps the leverage, and Curaleaf would likely need to change the form of payment, not just the figure.

Informational only, not investment advice. Figures and quotes come from the linked reports.